SCHEMBL16081047

SCHEMBL16081047

C[C@@]1(C#N)[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O[C@H]1n1cnc2c(N)nc(N)nc21

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 4/20 0.55
▸ P2RY1 P47900 3/20 0.55
▸ P2RX1 P51575 3/20 0.55
▸ ENPP1 P22413 2/20 0.55
▸ P2RX4 Q99571 2/20 0.55
▸ P2RY11 Q96G91 2/20 0.55
▸ P2RY6 Q15077 1/20 0.55
▸ P2RY12 Q9H244 2/20 0.54
▸ RNASEL Q05823 3/20 0.53
▸ IMPDH2 P12268 1/20 0.52
▸ IMPDH1 P20839 1/20 0.52
▸ GPR17 Q13304 2/20 0.51
▸ P2RX2 Q9UBL9 1/20 0.50
▸ NT5E P21589 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16081073 0.91 P2RX3 (0.48) P2RX3P2RY1P2RX1ENPP1P2RX4
SCHEMBL16081043 0.90 P2RX3 (0.63) P2RX3P2RY1P2RX1P2RX4RNASEL
SCHEMBL16081110 0.90 P2RY1 (0.58) P2RX3P2RY1P2RX1ENPP1P2RX4
SCHEMBL15908464 0.89 P2RX3 (0.57) P2RX3P2RY1P2RX1ENPP1P2RX4
SCHEMBL15910311 0.89 P2RX3 (0.57) P2RX3P2RY1P2RX1ENPP1P2RX4
SCHEMBL13976355 0.89 P2RX3 (0.57) P2RX3P2RY1P2RX1ENPP1P2RX4
SCHEMBL12849777 0.88 P2RY1 (0.57) P2RX3P2RY1P2RX1ENPP1P2RX4
SCHEMBL12878125 0.88 P2RY1 (0.57) P2RX3P2RY1P2RX1ENPP1P2RX4
SCHEMBL13976360 0.88 P2RY1 (0.57) P2RX3P2RY1P2RX1ENPP1P2RX4
SCHEMBL16480941 0.88 P2RY1 (0.57) P2RX3P2RY1P2RX1ENPP1P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10231986-B2 Amino acid phosphoramidate pronucleotides of 2′-cyano, azido and amino nucleosides for the treatment of HCV IDENIX PHARMACEUTICALS LLC (US) 2019-03-19 — — US disclosed
US-20160113956-A1 AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV UNIVERSITE DE MONTPELLIER (FR) 2016-04-28 — — US disclosed
US-20160113956-A1 AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV UNIVERSITE DE MONTPELLIER (FR) 2016-04-28 — — US disclosed
WO-2014160484-A1 AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS, INC. (US) 2014-10-02 — — WO disclosed
US-20140271547-A1 AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS, INC. 2014-09-18 — — US disclosed
US-20140271547-A1 AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS, INC. 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10231986-B2 Amino acid phosphoramidate pronucleotides of 2′-cyano, azido and amino nucleosides for the treatment of HCV PNP, RNGTT, NSUN2 P2RX3 145/4885P2RY1 26/4885P2RX1 85/4885
US-20160113956-A1 AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV PNP, RNGTT, NSUN2 P2RX3 144/4885P2RY1 26/4885P2RX1 84/4885
US-20140271547-A1 AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV PNP, RNGTT, NSUN2 P2RX3 144/4885P2RY1 26/4885P2RX1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback